Tempus AI Executives Report Mid‑August Sell‑to‑Cover Stock Sales

Company filings show the trades were preplanned tax‑withholding sales that drew attention because they occurred around a sharp stock rally tied to a vaccine readout and a Personalis deal linkage.

Overview

On Tuesday and Wednesday, August 18 and 19, SEC Form 4 filings reported that Tempus insiders executed sell‑to‑cover transactions to satisfy tax withholding on vested restricted stock units.
CFO James Rogers sold 48,842 shares and now holds 106,000 shares, COO accounting chief Ryan Bartolucci sold 6,175 shares and retains 67,866 shares, EVP Andrew Polovin sold 30,075 shares and keeps 138,140 shares, and director Nadja West sold 3,000 shares and retains 34,981 shares.
Several of the trades were carried out under pre‑established Rule 10b5‑1 trading plans or described as non‑discretionary, which means they were automatic executions tied to vesting and tax rules rather than ad hoc market timing.
The transactions were reported at prices below the August 19 close of $61.25, and the filings came as the stock was re‑priced after a Merck–Moderna Phase 3 vaccine readout and Personalis‑related demand signals increased investor interest.
Tempus remains a growth‑stage healthcare technology firm with about 3,800 employees, roughly $1.4 billion in trailing revenue and a recent market cap near $10.7 billion, and the disclosures underline governance transparency while insiders keep significant equity stakes.